Cycle Pharmaceuticals launches its first oncology product in US
PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a bespoke distribution network from McKesson, Cencora, and Cardinal Health.
PHYRAGO is a tyrosine kinase inhibitor indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML), adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL), and paediatric patients one year old and older with Ph+ CML in chronic phase, and newly diagnosed Ph+ ALL.
PHYRAGO is bioequivalent to Sprycel® (dasatinib) tablets and has the unique clinical benefit of allowing patients to take proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) concomitantly to help manage gastric acid disorders. To help patients with medication access, financial savings, and clinical support, Cycle Vita™ will be available to eligible* patients taking PHYRAGO.
Steve Fuller, Chief Strategy Officer at Cycle Pharmaceuticals said: “We are honoured to introduce PHYRAGO as a new treatment option for people living with Ph+ leukaemia.
“We understand the daily challenges that come with managing Ph+ CML and Ph+ ALL and our goal is to ease that burden - not just with an improved formulation of dasatinib, but through the individualised care and hands on support offered by our Cycle Vita programme. By enabling more flexibility in co-medication and providing a dedicated support team, we’re committed to helping patients and their families navigate treatment with greater confidence and peace of mind.”
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease community.
Headquartered at The Broers Building at JJ Thomson Avenue, the company focuses on rare genetic conditions in metabolic, immunology, urology, and oncology. In neurology, its focus is multiple sclerosis.
Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States.